These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 10167344)

  • 41. Health care economic analyses and value-based medicine.
    Brown MM; Brown GC; Sharma S; Landy J
    Surv Ophthalmol; 2003; 48(2):204-23. PubMed ID: 12686305
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Health outcome models for policy analysis.
    Kaplan RM
    Health Psychol; 1989; 8(6):723-35. PubMed ID: 2517783
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions.
    Owens DK; Qaseem A; Chou R; Shekelle P;
    Ann Intern Med; 2011 Feb; 154(3):174-80. PubMed ID: 21282697
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preferences for health outcomes and cost-utility analysis.
    Torrance GW
    Am J Manag Care; 1997 May; 3 Suppl():S8-20. PubMed ID: 10180342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost-Effectiveness Analysis.
    van Baal P; Meltzer D; Brouwer W
    Health Econ; 2016 Feb; 25(2):237-48. PubMed ID: 25533778
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Cost-effectiveness--limits between optimization and rationing].
    Ruof J; Schöffski O
    Z Rheumatol; 1998 Oct; 57(5):340-4. PubMed ID: 9864843
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Review of methods to determine VA health care costs.
    Barnett PG
    Med Care; 1999 Apr; 37(4 Suppl Va):AS9-17. PubMed ID: 10217380
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration.
    Losina E; Michl G; Collins JE; Hunter DJ; Jordan JM; Yelin E; Paltiel AD; Katz JN
    Osteoarthritis Cartilage; 2016 May; 24(5):776-85. PubMed ID: 26746146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Rationing in German health care with particular consideration of oncology: view points of German stakeholders--a qualitative interview study].
    Lange J; Gönner C; Vollmann J; Rauprich O
    Gesundheitswesen; 2015 Jan; 77(1):8-15. PubMed ID: 24696371
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness analysis and health policy.
    Torgerson DJ
    Nestle Nutr Workshop Ser Clin Perform Programme; 2009; 12():95-104. PubMed ID: 19858689
    [TBL] [Abstract][Full Text] [Related]  

  • 51. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
    Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
    Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The cost-effectiveness of forty health interventions in Guinea.
    Jha P; Bangoura O; Ranson K
    Health Policy Plan; 1998 Sep; 13(3):249-62. PubMed ID: 10187595
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A cost-utility analysis of therapy for amblyopia.
    Membreno JH; Brown MM; Brown GC; Sharma S; Beauchamp GR
    Ophthalmology; 2002 Dec; 109(12):2265-71. PubMed ID: 12466169
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness analysis and policy choices: investing in health systems.
    Murray CJ; Kreuser J; Whang W
    Bull World Health Organ; 1994; 72(4):663-74. PubMed ID: 7923545
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of the U.S. panel on cost-effectiveness in health and medicine.
    Phillips KA; Chen JL
    Am J Prev Med; 2002 Feb; 22(2):98-105. PubMed ID: 11818178
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The economic evaluation of health care.
    Haas M; Hall J
    Health Inf Manag; 1998 Dec-1999 Feb; 28(4):169-72. PubMed ID: 10387363
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Should the consumption of survivors be included as a cost in cost-utility analysis?
    Nyman JA
    Health Econ; 2004 May; 13(5):417-27. PubMed ID: 15127422
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Economic evaluation and health care decision-making.
    Rutten F
    Health Policy; 1996 Jun; 36(3):215-29. PubMed ID: 10158267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of physicians in controlling medical care costs and reducing waste.
    Brook RH
    JAMA; 2011 Aug; 306(6):650-1. PubMed ID: 21828329
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.